RT Journal Article
SR Electronic
T1 Multidrug-resistant tuberculosis around the world: what progress has been made?
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP erj01018-2014
DO 10.1183/09031936.00101814
A1 Dennis Falzon
A1 Fuad Mirzayev
A1 Fraser Wares
A1 Inés Garcia Baena
A1 Matteo Zignol
A1 Nguyen Linh
A1 Karin Weyer
A1 Ernesto Jaramillo
A1 Katherine Floyd
A1 Mario Raviglione
YR 2014
UL http://erj.ersjournals.com/content/early/2014/10/16/09031936.00101814.abstract
AB Multidrug-resistant tuberculosis (MDR-TB) (resistance to at least isoniazid and rifampicin) will influence the future of global TB control. 88% of estimated MDR-TB cases occur in middle- or high-income countries, and 60% occur in Brazil, China, India, the Russian Federation and South Africa. The World Health Organization collects country data annually to monitor the response to MDR-TB. Notification, treatment enrolment and outcome data were summarised for 30 countries, accounting for >90% of the estimated MDR-TB cases among notified TB cases worldwide. In 2012, a median of 14% (interquartile range 6–50%) of estimated MDR-TB cases were notified in the 30 countries studied. In 15 of the 30 countries, the number of patients treated for MDR-TB in 2012 (71 681) was >50% higher than in 2011. Median treatment success was 53% (interquartile range 40–70%) in the 25 countries reporting data for 30 021 MDR-TB cases who started treatment in 2010. Although progress has been noted in the expansion of MDR-TB care, urgent efforts are required in order to provide wider access to diagnosis and treatment in most countries with the highest burden of MDR-TB. A wider adoption of effective diagnostics, treatment and preventive measures is needed to control MDR-TB globally http://ow.ly/zwZWr